Looking for 151038-96-9 / Aldoxorubicin API manufacturers, exporters & distributors?
Aldoxorubicin manufacturers, exporters & distributors
1
20
PharmaCompass offers a list of Aldoxorubicin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Aldoxorubicin manufacturer or Aldoxorubicin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Aldoxorubicin manufacturer or Aldoxorubicin supplier.
API | Excipient name
Aldoxorubicin
Synonyms
Inno-206, 1361644-26-9, Doxorubicin-emch, Doxo-emch, Aldoxorubicin [usan], N-[(e)-[1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide
Unique Ingredient Identifier (UNII)
C28MV4IM0B
About Aldoxorubicin
Aldoxorubicin is a 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity. Following intravenous administration, aldoxorubicin binds selectively to the cysteine-34 position of albumin via its maleimide moiety. Doxorubicin is released from the albumin carrier after cleavage of the acid-sensitive hydrazone linker within the acidic environment of tumors and, once located intracellularly, intercalates DNA, inhibits DNA synthesis, and induces apoptosis. Albumin tends to accumulate in solid tumors as a result of high metabolic turnover, rapid angiogenesis, hypervasculature, and impaired lymphatic drainage. Because of passive accumulation within tumors, this agent may improve the therapeutic effects of doxorubicin while minimizing systemic toxicity.